Terug
42
Dagbereik
€ 96,82
€ 98,71
52-Weeksbereik
€ 92,77
€ 127,99
Volume
627.256
50D / 200D Gem.
€ 102,88
/
€ 113,90
Vorige Slotkoers
€ 97,52
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 17,3 | 0,3 |
| P/B | 4,0 | 2,9 |
| ROE % | 25,1 | 3,7 |
| Net Margin % | 9,5 | 3,8 |
| Rev Growth 5Y % | 10,3 | 10,0 |
| D/E | 1,1 | 0,2 |
Koersdoel Analisten
Hold
€ 151,50
+55.4%
Low: € 150,00
High: € 153,00
Forward K/W
16,5
Forward WPA
€ 5,92
WPA Groei (sch.)
+0,0%
Omzet Sch.
6,4 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 7,69
€ 7,65 – € 7,76
|
7,9 B | 1 |
| FY2028 |
€ 7,04
€ 6,95 – € 7,12
|
7,5 B | 2 |
| FY2027 |
€ 6,47
€ 6,05 – € 6,65
|
6,9 B | 8 |
Belangrijkste Punten
Revenue grew 10,27% annually over 5 years — strong growth
Earnings grew 24,25% over the past year
ROE of 25,14% indicates high profitability
Generating 439,20M in free cash flow
PEG of 0,78 suggests growth is underpriced
ROIC of 15,33% — excellent capital efficiency
Groei
Revenue Growth (5Y)
10,27%
Revenue (1Y)10,46%
Earnings (1Y)24,25%
FCF Growth (3Y)28,09%
Kwaliteit
Return on Equity
25,14%
ROIC15,33%
Net Margin9,54%
Op. Margin17,74%
Veiligheid
Debt / Equity
1,11
Current Ratio1,08
Interest Coverage8,55
Waardering
P/E Ratio
17,32
P/B Ratio4,02
EV/EBITDA11,79
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,46% | Revenue Growth (3Y) | 11,18% |
| Earnings Growth (1Y) | 24,25% | Earnings Growth (3Y) | 26,83% |
| Revenue Growth (5Y) | 10,27% | Earnings Growth (5Y) | 8,26% |
| Profitability | |||
| Revenue (TTM) | 5,94B | Net Income (TTM) | 566,20M |
| ROE | 25,14% | ROA | 7,99% |
| Gross Margin | 21,72% | Operating Margin | 17,74% |
| Net Margin | 9,54% | Free Cash Flow (TTM) | 439,20M |
| ROIC | 15,33% | FCF Growth (3Y) | 28,09% |
| Safety | |||
| Debt / Equity | 1,11 | Current Ratio | 1,08 |
| Interest Coverage | 8,55 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 17,32 | P/B Ratio | 4,02 |
| P/S Ratio | 1,65 | PEG Ratio | 0,78 |
| EV/EBITDA | 11,79 | Dividend Yield | 0,01% |
| Market Cap | 9,81B | Enterprise Value | 12,42B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5,94B | 5,37B | 4,80B | 4,35B | 4,01B |
| Net Income | 566,20M | 455,70M | 352,00M | 271,00M | 412,20M |
| EPS (Diluted) | 5,55 | 4,46 | 3,47 | 2,70 | 4,11 |
| Gross Profit | 1,29B | 2,23B | 1,98B | 1,75B | 1,70B |
| Operating Income | 1,05B | 864,50M | 1,72B | 630,20M | 659,40M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7,09B | 6,53B | 6,10B | 5,64B | 6,86B |
| Total Liabilities | 3,81B | 3,69B | 3,81B | 3,77B | 4,47B |
| Shareholders' Equity | 2,44B | 2,07B | 1,65B | 1,31B | 1,91B |
| Total Debt | 2,71B | 2,71B | 2,93B | 2,99B | 3,48B |
| Cash & Equivalents | 102,90M | 85,40M | 104,20M | 21,80M | 49,40M |
| Current Assets | 905,90M | 886,90M | 841,80M | 717,20M | 921,40M |
| Current Liabilities | 836,40M | 841,00M | 656,40M | 575,90M | 748,80M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#235 of 332
Recente Activiteit
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026